BPG is committed to discovery and dissemination of knowledge
Articles in Press
2/5/2026 10:10:56 AM | Browse: 3 | Download: 0
| Category |
Psychiatry |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Unpacking the promise and peril of celecoxib and duloxetine in knee osteoarthritis management
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Takahiko Nagamine |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Takahiko Nagamine, Department of Psychiatric Internal Medicine, Sunlight Brain Research Center, 4-13-18 Jiyugaoka, Hofu 7470066, Yamaguchi, Japan. tnagamine@outlook.com |
| Key Words |
Celecoxib; Duloxetine; Insomnia; Osteoarthritis; Adverse events |
| Core Tip |
Combining celecoxib and duloxetine is more effective than celecoxib alone for pain, depression, and anxiety in knee osteoarthritis. However, its assertion of safety after only eight weeks is overly optimistic. Prescribers must be warned about the serious long-term risks that were not adequately covered. Celecoxib carries established cardiovascular and gastrointestinal risks, while duloxetine poses significant risks for hepatotoxicity, central nervous system side effects (like dizziness and falls), and a severe discontinuation syndrome. Given the older people, often comorbid knee osteoarthritis population, the combination requires thorough cardiovascular and hepatic screening, meticulous review for drug-drug interactions, and informed consent regarding the mandatory slow tapering of duloxetine. The evidence is preliminary; this dual-action treatment should be reserved for patients who have failed simpler strategies. |
| Citation |
Nagamine T. Unpacking the promise and peril of celecoxib and duloxetine in knee osteoarthritis management. World J Psychiatry 2026; In press |
 |
Received |
|
2025-11-06 06:11 |
 |
Peer-Review Started |
|
2025-11-06 06:26 |
 |
First Decision by Editorial Office Director |
|
2025-12-19 08:03 |
 |
Return for Revision |
|
2025-12-19 08:03 |
 |
Revised |
|
2025-12-20 06:10 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2026-02-05 02:44 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-02-05 10:10 |
 |
Articles in Press |
|
2026-02-05 10:10 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345